Sharyn Baker

Image
Sharyn Baker

Sharyn Baker, PharmD, PhD

Title
Gertrude Parker Heer Chair in Cancer Research,
Secondary Title
Professor and Chair
Unit / Department / Division
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences Affiliated Faculty
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations. Dr. Baker’s research interests include developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anti-cancer drug disposition and investigational anti-cancer drug development.

Education

  • 2004, Ph.D., Erasmus University Rotterdam, Medicine
  • 1991, Pharm.D., University of California, San Francisco, Pharmacy
  • 1986, B.A., Pacific Lutheran University, Biology
  • California State Board of Pharmacy No. 40219 (inac, California State Board of Pharmacy

Honors

  • ASCPT Clinical and Translational Science Award, 2017
  • The Ohio State University Distinguished Scholar Award, 2022

Publications

  • A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities, Pharmaceutics. 2022 Sep | journal-article. doi: 10.3390/pharmaceutics14091933.
  • BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors., Blood advances. 2022 Jul | journal-article. doi: 10.1182/bloodadvances.2022007952.
  • Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication., Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Mar | journal-article. doi: 10.1158/1078-0432.ccr-21-4450.
  • Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination., Pharmaceutics. 2022 Mar | journal-article. doi: 10.3390/pharmaceutics14040694.
  • The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321., Cancer chemotherapy and pharmacology. 2022 Jan | journal-article. doi: 10.1007/s00280-022-04397-4.
  • Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia., Blood advances. 2021 Dec | journal-article. doi: 10.1182/bloodadvances.2021005614.
  • Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition., Cancer research communications. 2021 Nov | journal-article. doi: 10.1158/2767-9764.crc-21-0076.
  • Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition., Kidney international. 2021 Sep | journal-article. doi: 10.1016/j.kint.2021.08.022.
  • Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML., Molecular cancer therapeutics. 2021 Sep | journal-article. doi: 10.1158/1535-7163.mct-21-0071.
  • Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators., Blood cancer discovery. 2021 Sep | journal-article. doi: 10.1158/2643-3230.bcd-21-0049.
  • Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2021 Jul | journal-article. doi: 10.1016/j.jchromb.2021.122882.
  • Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions., Basic & clinical pharmacology & toxicology. 2021 Jun | journal-article. doi: 10.1111/bcpt.13623.
  • Targeting OCT3 attenuates doxorubicin-induced cardiac injury., Proceedings of the National Academy of Sciences of the United States of America. 2021 Feb | journal-article. doi: 10.1073/pnas.2020168118.
  • TP-0903 is active in models of drug-resistant acute myeloid leukemia., JCI insight. 2020 Dec | journal-article. doi: 10.1172/jci.insight.140169.
  • DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia., Clinical and translational science. 2020 Sep | journal-article. doi: 10.1111/cts.12861.
  • Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors., Pharmaceutics. 2020 Sep | journal-article. doi: 10.3390/pharmaceutics12090856.
  • Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib., Pharmaceutics. 2020 Aug | journal-article. doi: 10.3390/pharmaceutics12090788.
  • Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 May | journal-article. doi: 10.1016/j.jchromb.2020.122176.
  • A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury., Nature communications. 2020 Apr | journal-article. doi: 10.1038/s41467-020-15638-6.
  • Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions., Drug metabolism and disposition: the biological fate of chemicals. 2020 Feb | journal-article. doi: 10.1124/dmd.119.090316.
  • Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia., Journal of hematology & oncology. 2020 Jan | journal-article. doi: 10.1186/s13045-019-0821-7.
  • Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice., Pharmacology research & perspectives. 2019 Dec | journal-article. doi: 10.1002/prp2.534.
  • Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1., Clinical pharmacology and therapeutics. 2019 Sep | journal-article. doi: 10.1002/cpt.1588.
  • Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies., Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug | journal-article. doi: 10.1158/1078-0432.ccr-19-0470.
  • Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML., Clinical and translational science. 2019 Aug | journal-article. doi: 10.1111/cts.12669.
  • Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML., Investigational new drugs. 2019 May | journal-article. doi: 10.1007/s10637-019-00786-4.
  • A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML., Nature communications. 2019 May | journal-article. doi: 10.1038/s41467-019-09917-0.
  • Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice., Clinical and translational science. 2019 Apr | journal-article. doi: 10.1111/cts.12630.
  • Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms., Nature communications. 2019 Jan | journal-article. doi: 10.1038/s41467-018-08263-x.
  • Hypoxia Reporter Element Assay., Bio-protocol. 2018 Aug | journal-article. doi: 10.21769/bioprotoc.2951.
  • Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 May | journal-article. doi: 10.1016/j.jchromb.2018.05.005.
  • Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia, Journal of Clinical Investigation. 2018 Jan | journal-article. doi: 10.1172/JCI91893.
  • Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations., British journal of cancer. 2017 Jul | journal-article. doi: 10.1038/bjc.2017.217.
  • Kinase Inhibitors: The Reality Behind the Success, Clinical Pharmacology and Therapeutics. 2017 Jan | journal-article. doi: 10.1002/cpt.815.
  • Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation, Leukemia and Lymphoma. 2017 Jan | journal-article. doi: 10.1080/10428194.2016.1187272.
  • Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine, Cancer. 2017 Jan | journal-article. doi: 10.1002/cncr.30762.
  • OCTN1 is a high-affinity carrier of nucleoside analogues, Cancer Research. 2017 Jan | journal-article. doi: 10.1158/0008-5472.CAN-16-2548.
  • Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia, ACS Omega. 2017 Jan | journal-article. doi: 10.1021/acsomega.7b00144.
  • Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12458.
  • Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12480.
  • E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia, Leukemia. 2017 Jan | journal-article. doi: 10.1038/leu.2016.293.
  • A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10-03), Pediatric Blood and Cancer. 2017 Jan | journal-article. doi: 10.1002/pbc.26414.
  • Evaluation of artemisinins for the treatment of acute myeloid leukemia, Cancer Chemotherapy and Pharmacology. 2016 Jan | journal-article. doi: 10.1007/s00280-016-3038-2.
  • Sorafenib metabolism, transport, and enterohepatic recycling: Physiologically based modeling and simulation in mice, Cancer Chemotherapy and Pharmacology. 2016 Jan | journal-article. doi: 10.1007/s00280-016-3018-6.
  • Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia, Clinical Pharmacology and Therapeutics. 2016 Jan | journal-article. doi: 10.1002/cpt.315.
  • Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death, Cancer Research. 2016 Jan | journal-article. doi: 10.1158/0008-5472.CAN-15-0694.
  • Design, synthesis and evaluation of anti-CD123 antibody drug conjugates, Bioorganic and Medicinal Chemistry. 2016 Jan | journal-article. doi: 10.1016/j.bmc.2016.09.043.
  • ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression, Clinical and Translational Science. 2016 Jan | journal-article. doi: 10.1111/cts.12366.
  • Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88] DOI: 10.1016/j.jchromb.2004.09.012, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2016 Jan | journal-article. doi: 10.1016/j.jchromb.2016.03.018.
  • Clinical significance of in vivo cytarabine-induced gene expression signature in AML, Leukemia and Lymphoma. 2016 Jan | journal-article. doi: 10.3109/10428194.2015.1086918.
  • A phosphotyrosine switch regulates organic cation transporters, Nature Communications. 2016 Jan | journal-article. doi: 10.1038/ncomms10880.
  • Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia, Cancer Cell. 2015 Jan | journal-article. doi: 10.1016/j.ccell.2015.07.016.
  • Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b, Cancer Research. 2015 Jan | journal-article. doi: 10.1158/0008-5472.CAN-15-0280.
  • Pharmacokinetics and pharmacodynamics of anticancer drugs, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Tenth Edition. 2015 Jan | book. .
  • Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1), Clinical Cancer Research. 2014 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-1999.
  • Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy | Invloedvan roken op farmacokinetiek en toxiciteit van taxanen, Pharmaceutisch Weekblad. 2014 Jan | journal-article. .
  • Inhibition of OATP1B1 by tyrosine kinase inhibitors: In vitro-in vivo correlations, British Journal of Cancer. 2014 Jan | journal-article. doi: 10.1038/bjc.2013.811.
  • Integrating clinical pharmacology concepts in individualized therapy with Tyrosine Kinase inhibitors, Clinical Pharmacology and Therapeutics. 2013 Jan | journal-article. doi: 10.1038/clpt.2012.247.
  • The genomic landscape of hypodiploid acute lymphoblastic leukemia, Nature Genetics. 2013 Jan | journal-article. doi: 10.1038/ng.2532.
  • Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-0306.
  • Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-1897.
  • Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51, PLoS ONE. 2013 Jan | journal-article. doi: 10.1371/journal.pone.0079106.
  • Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-3306.
  • Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-1323.
  • Crenolanib is active against models of drug-resistant FLT3-ITD - Positive acute myeloid leukemia, Blood. 2013 Jan | journal-article. doi: 10.1182/blood-2013-07-513044.
  • Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246)), Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-0503.
  • Alternative formulations of sorafenib for use in children, Pediatric Blood and Cancer. 2013 Jan | journal-article. doi: 10.1002/pbc.24619.
  • Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-13-0980.
  • Inhibition of OCTN2-mediated transport of carnitine by etoposide, Molecular Cancer Therapeutics. 2012 Jan | journal-article. doi: 10.1158/1535-7163.MCT-11-0980.
  • Ontogeny and sorafenib metabolism, Clinical Cancer Research. 2012 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-1967.
  • OATP1B1 polymorphism as a determinant of erythromycin disposition, Clinical Pharmacology and Therapeutics. 2012 Jan | journal-article. doi: 10.1038/clpt.2012.106.
  • Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy, Clinical Cancer Research. 2012 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-0728.
  • Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel, Clinical Cancer Research. 2012 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-0761.
  • Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents, British Journal of Cancer. 2012 Jan | journal-article. doi: 10.1038/bjc.2012.357.
  • Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia, Journal of the National Cancer Institute. 2011 Jan | journal-article. doi: 10.1093/jnci/djr107.
  • CREBBP mutations in relapsed acute lymphoblastic leukaemia, Nature. 2011 Jan | journal-article. doi: 10.1038/nature09727.
  • Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF, Leukemia Research. 2011 Jan | journal-article. doi: 10.1016/j.leukres.2010.06.001.
  • Docetaxel metabolism is not altered by imatinib: Findings from an early phase study in metastatic breast cancer, Breast Cancer Research and Treatment. 2011 Jan | journal-article. doi: 10.1007/s10549-011-1413-6.
  • Effect of ABCC2 (MRP2) transport function on erythromycin metabolism, Clinical Pharmacology and Therapeutics. 2011 Jan | journal-article. doi: 10.1038/clpt.2011.25.
  • Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes, Pharmacogenomics. 2011 Jan | journal-article. doi: 10.2217/pgs.10.191.
  • Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemotherapy and Pharmacology. 2011 Jan | journal-article. doi: 10.1007/s00280-010-1367-0.
  • Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia, Journal of Clinical Oncology. 2011 Jan | journal-article. doi: 10.1200/JCO.2011.34.7427.
  • Reply to J. Gligorov et al, Journal of Clinical Oncology. 2011 Jan | journal-article. doi: 10.1200/JCO.2011.34.6734.
  • Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer, Investigational New Drugs. 2011 Jan | journal-article. doi: 10.1007/s10637-010-9413-7.
  • Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2010 Jan | journal-article. doi: 10.1016/j.jchromb.2010.08.049.
  • Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer, Journal of Clinical Oncology. 2010 Jan | journal-article. doi: 10.1200/JCO.2010.30.7025.
  • A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias, Leukemia. 2010 Jan | journal-article. doi: 10.1038/leu.2010.132.
  • A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors, Clinical Cancer Research. 2009 Jan | journal-article. doi: 10.1158/1078-0432.CCR-09-0567.
  • Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters, Clinical Cancer Research. 2009 Jan | journal-article. doi: 10.1158/1078-0432.CCR-09-0048.
  • Pharmacogenetic pathway analysis of docetaxel elimination, Clinical Pharmacology and Therapeutics. 2009 Jan | journal-article. doi: 10.1038/clpt.2008.95.
  • Pharmacokinetic considerations for new targeted therapies, Clinical Pharmacology and Therapeutics. 2009 Jan | journal-article. doi: 10.1038/clpt.2008.242.
  • Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men with Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers, Journal of Clinical Oncology. 2009 Jan | journal-article. doi: 10.1200/JCO.2009.21.9410.
  • Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation. 2009 Jan | journal-article. doi: 10.1016/j.bbmt.2008.11.027.
  • Stability of sunitinib in oral suspension, Annals of Pharmacotherapy. 2008 Jan | journal-article. doi: 10.1345/aph.1K654.
  • Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2008 Jan | journal-article. doi: 10.1016/j.jchromb.2008.09.007.
  • Phase I study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumors, Journal of Clinical Oncology. 2008 Jan | journal-article. doi: 10.1200/JCO.2008.17.9788.
  • Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements, Clinical Pharmacology and Therapeutics. 2008 Jan | journal-article. doi: 10.1038/sj.clpt.6100476.
  • Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer, Journal of Clinical Oncology. 2008 Jan | journal-article. doi: 10.1200/JCO.2007.15.1928.
  • Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies, Annals of Oncology. 2008 Jan | journal-article. doi: 10.1093/annonc/mdm572.
  • Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acidin cancer patients, Clinical Cancer Research. 2008 Jan | journal-article. doi: 10.1158/1078-0432.CCR-07-1475.
  • Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors, Cancer Chemotherapy and Pharmacology. 2008 Jan | journal-article. doi: 10.1007/s00280-007-0485-9.
  • Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib, Clinical Pharmacology and Therapeutics. 2008 Jan | journal-article. doi: 10.1038/sj.clpt.6100320.
  • Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia, Molecular Cancer Therapeutics. 2008 Jan | journal-article. doi: 10.1158/1535-7163.MCT-07-2218.
  • Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors, Journal of Clinical Oncology. 2008 Jan | journal-article. doi: 10.1200/JCO.2008.16.2347.
  • Influence of solute carriers on the pharmacokinetics of CYP3A4 probes, Clinical Pharmacology and Therapeutics. 2008 Jan | journal-article. doi: 10.1038/clpt.2008.94.
  • Interaction of imatinib with human organic ion carriers, Clinical Cancer Research. 2008 Jan | journal-article. doi: 10.1158/1078-0432.CCR-07-4913.
  • Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100, British Journal of Cancer. 2008 Jan | journal-article. doi: 10.1038/sj.bjc.6604353.
  • Erratum: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors (Cancer Research (2004) 64, (9139-9143)), Cancer Research. 2007 Jan | journal-article. doi: 10.1158/0008-5472.CAN-67-16-COR1.
  • Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours, European Journal of Cancer. 2007 Jan | journal-article. doi: 10.1016/j.ejca.2006.09.006.
  • Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers, Investigational New Drugs. 2007 Jan | journal-article. doi: 10.1007/s10637-006-9028-1.
  • A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma, Journal of Pharmaceutical and Biomedical Analysis. 2007 Jan | journal-article. doi: 10.1016/j.jpba.2006.08.006.
  • Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib, Clinical Cancer Research. 2007 Jan | journal-article. doi: 10.1158/1078-0432.CCR-07-0346.
  • Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes, Clinical Cancer Research. 2007 Jan | journal-article. doi: 10.1158/1078-0432.CCR-07-0088.
  • Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models, Cancer Biology and Therapy. 2007 Jan | journal-article. doi: 10.4161/cbt.6.6.4096.
  • Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients, Cancer Biology and Therapy. 2007 Jan | journal-article. doi: 10.4161/cbt.6.3.3763.
  • Activated pregnenolone X-receptor is a target for ketoconazole and its analogs, Clinical Cancer Research. 2007 Jan | journal-article. doi: 10.1158/1078-0432.CCR-06-1592.
  • A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2007 Jan | journal-article. doi: 10.1016/j.jchromb.2006.06.005.
  • Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese, Journal of Clinical Oncology. 2007 Jan | journal-article. doi: 10.1200/JCO.2007.11.2938.
  • Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors, Clinical Cancer Research. 2006 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-1942.
  • Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies, Journal of Pharmaceutical and Biomedical Analysis. 2006 Jan | journal-article. doi: 10.1016/j.jpba.2006.04.010.
  • Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer, Clinical Cancer Research. 2006 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-1834.
  • Targeting early stage DCIS breast cancer directly in the ducts with intraductal chemotherapy, Cancer Biology and Therapy. 2006 Jan | journal-article. .
  • Predicting vinorelbine disposition and toxicity: Does BSA provide more than a "bad statistical association"?, Journal of Clinical Oncology. 2006 Jan | journal-article. doi: 10.1200/JCO.2005.05.4494.
  • Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue, Clinical Cancer Research. 2006 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-2249.
  • Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma, American Journal of Clinical Oncology: Cancer Clinical Trials. 2006 Jan | journal-article. doi: 10.1097/01.coc.0000225411.95479.b4.
  • Pharmacokinetics and toxicity of weekly docetaxel in older patients, Clinical Cancer Research. 2006 Jan | journal-article. doi: 10.1158/1078-0432.CCR-06-0200.
  • Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: In vitro and in cancer patients, Investigational New Drugs. 2006 Jan | journal-article. doi: 10.1007/s10637-006-5269-2.
  • A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies, Investigational New Drugs. 2006 Jan | journal-article. doi: 10.1007/s10637-006-8219-0.
  • Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib, Clinical Pharmacology and Therapeutics. 2006 Jan | journal-article. doi: 10.1016/j.clpt.2006.05.003.
  • Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function, Journal of Clinical Oncology. 2006 Jan | journal-article. doi: 10.1200/JCO.2004.00.9720.
  • CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors, Journal of the National Cancer Institute. 2006 Jan | journal-article. doi: 10.1093/jnci/djj466.
  • Clinical pharmacokinetics of docetaxel: Recent developments, Clinical Pharmacokinetics. 2006 Jan | journal-article. doi: 10.2165/00003088-200645030-00002.
  • Ductal access for prevention and therapy of mammary tumors, Cancer Research. 2006 Jan | journal-article. doi: 10.1158/0008-5472.CAN-05-4329.
  • Pharmacogenetics of ABCG2 and adverse reactions to gefitinib, Journal of the National Cancer Institute. 2006 Jan | journal-article. doi: 10.1093/jnci/djj469.
  • Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry, Analytical Biochemistry. 2005 Jan | journal-article. doi: 10.1016/j.ab.2004.10.030.
  • Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2005 Jan | journal-article. doi: 10.1016/j.jchromb.2005.09.027.
  • Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2005 Jan | journal-article. doi: 10.1016/j.jchromb.2005.01.027.
  • Relationship of systemic exposure to unbound docetaxel and neutropenia, Clinical Pharmacology and Therapeutics. 2005 Jan | journal-article. doi: 10.1016/j.clpt.2004.09.005.
  • Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly, Journal of Clinical Oncology. 2005 Jan | journal-article. doi: 10.1200/JCO.2005.03.082.
  • Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies, Journal of Clinical Oncology. 2005 Jan | journal-article. doi: 10.1200/JCO.2005.07.450.
  • Paclitaxel repackaged in an albumin-stabilized nanoparticle: Handy or just a dandy?, Journal of Clinical Oncology. 2005 Jan | journal-article. doi: 10.1200/JCO.2005.03.7135.
  • Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study, Neuro-Oncology. 2005 Jan | journal-article. doi: 10.1215/S1152851704000183.
  • Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan, Clinical Cancer Research. 2005 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-1288.
  • Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients, Clinical Cancer Research. 2005 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-0520.
  • A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection, Journal of Pharmaceutical and Biomedical Analysis. 2005 Jan | journal-article. doi: 10.1016/j.jpba.2004.10.052.
  • A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors, Clinical Cancer Research. 2005 Jan | journal-article. .
  • In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent, Clinical Cancer Research. 2005 Jan | journal-article. doi: 10.1158/1078-0432.CCR-05-1037.
  • Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy, European Journal of Cancer. 2004 Jan | journal-article. doi: 10.1016/j.ejca.2003.12.026.
  • Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study, Pharmacotherapy. 2004 Jan | journal-article. doi: 10.1592/phco.24.1.16.34800.
  • Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry, Steroids. 2004 Jan | journal-article. doi: 10.1016/j.steroids.2004.05.020.
  • Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry, Analytical Biochemistry. 2004 Jan | journal-article. doi: 10.1016/j.ab.2003.09.038.
  • Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2004 Jan | journal-article. doi: 10.1016/j.jchromb.2004.09.012.
  • Limited cerebrospinal fluid penetration of docetaxel, Anti-Cancer Drugs. 2004 Jan | journal-article. doi: 10.1097/01.cad.0000136882.19552.8f.
  • Factors affecting cytochrome P-450 3A activity in cancer patients, Clinical Cancer Research. 2004 Jan | journal-article. doi: 10.1158/1078-0432.CCR-04-1371.
  • Determination of fraction unbound docetaxel using microequilibrium dialysis, Analytical Biochemistry. 2004 Jan | journal-article. doi: 10.1016/j.ab.2004.03.045.
  • Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel, Clinical Cancer Research. 2004 Jan | journal-article. doi: 10.1158/1078-0432.CCR-0842-03.
  • An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors, Cancer Research. 2004 Jan | journal-article. doi: 10.1158/0008-5472.CAN-04-1036.
  • A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV, Biomedical Chromatography. 2004 Jan | journal-article. doi: 10.1002/bmc.314.
  • Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel, Clinical Pharmacology and Therapeutics. 2004 Jan | journal-article. doi: 10.1016/j.clpt.2004.01.001.
  • Irinotecan pathway genotype analysis to predict pharmacokinetics, Clinical Cancer Research. 2003 Jan | journal-article. .
  • Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report., Oncology (Williston Park, N.Y.). 2003 Jan | journal-article. .
  • Phase I trial of continuous infusion 5-aza-2′-deoxycytidine, Cancer Chemotherapy and Pharmacology. 2003 Jan | journal-article. .
  • Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile, Clinical Cancer Research. 2003 Jan | journal-article. .
  • Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2003 Jan | journal-article. doi: 10.1016/S1570-0232(03)00356-8.
  • Distribution of paclitaxel in plasma and cerebrospinal fluid, Anti-Cancer Drugs. 2003 Jan | journal-article. doi: 10.1097/00001813-200306000-00007.
  • Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches, Clinical Pharmacology and Therapeutics. 2003 Jan | journal-article. doi: 10.1016/j.clpt.2003.08.004.
  • Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: In vitro and clinical pharmacokinetic studies, Clinical Cancer Research. 2003 Jan | journal-article. .
  • Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins, Clinical Pharmacology and Therapeutics. 2003 Jan | journal-article. doi: 10.1016/S0009-9236(03)00222-4.
  • A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS, Journal of Pharmaceutical and Biomedical Analysis. 2003 Jan | journal-article. doi: 10.1016/S0731-7085(03)00424-2.
  • Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, Journal of Clinical Oncology. 2002 Jan | journal-article. doi: 10.1200/JCO.20.1.96.
  • Troxacitabine in patients with refractory leukemia [1] (multiple letters), Journal of Clinical Oncology. 2002 Jan | journal-article. doi: 10.1200/JCO.2002.99.902.
  • Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001, Journal of the National Cancer Institute. 2002 Jan | journal-article. doi: 10.1093/jnci/94.24.1883.
  • Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia, Journal of Clinical Oncology. 2002 Jan | journal-article. doi: 10.1200/JCO.20.3.656.
  • Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days, Journal of Clinical Oncology. 2002 Jan | journal-article. doi: 10.1200/JCO.2002.12.047.
  • Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy, Molecular Cancer Therapeutics. 2002 Jan | journal-article. .
  • Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2002 Jan | journal-article. doi: 10.1016/S1570-0232(02)00167-8.
  • A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies, Clinical Cancer Research. 2001 Jan | journal-article. .
  • Troxarcitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia, Journal of Clinical Oncology. 2001 Jan | journal-article. .
  • Tumor targeting by conjugation of DHA to paclitaxel, Journal of Controlled Release. 2001 Jan | journal-article. doi: 10.1016/S0168-3659(01)00321-2.
  • Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel, Clinical Cancer Research. 2001 Jan | journal-article. .
  • Population pharmacokinetic model for topotecan derived from phase I clinical trials, Journal of Clinical Oncology. 2000 Jan | journal-article. doi: 10.1200/JCO.2000.18.12.2459.
  • Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, Journal of Clinical Oncology. 2000 Jan | journal-article. .
  • Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: A gynecologic oncology group study, American Journal of Clinical Oncology: Cancer Clinical Trials. 2000 Jan | journal-article. doi: 10.1097/00000421-200012000-00017.
  • Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel, Clinical Cancer Research. 2000 Jan | journal-article. .
  • Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, Journal of Clinical Oncology. 2000 Jan | journal-article. doi: 10.1200/JCO.2000.18.24.4086.
  • Pharmacology of fluorinated pyrimidines: Eniluracil, Investigational New Drugs. 2000 Jan | journal-article. doi: 10.1023/A:1006453500629.
  • A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077, Clinical Cancer Research. 2000 Jan | journal-article. .
  • A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, Clinical Cancer Research. 1999 Jan | journal-article. .
  • A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, Clinical Cancer Research. 1999 Jan | journal-article. .
  • A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation, Cancer Chemotherapy and Pharmacology. 1999 Jan | journal-article. doi: 10.1007/s002800050992.
  • Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer, Clinical Cancer Research. 1999 Jan | journal-article. .
  • Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin, Clinical Cancer Research. 1999 Jan | journal-article. .
  • Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies, Journal of Clinical Oncology. 1999 Jan | journal-article. .
  • Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, Journal of Clinical Oncology. 1999 Jan | journal-article. .
  • Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies, Journal of Clinical Oncology. 1998 Jan | journal-article. doi: 10.1200/JCO.1998.16.8.2770.
  • Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks, Clinical Cancer Research. 1998 Jan | journal-article. .
  • High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and parmacodynamic study, Annals of Oncology. 1998 Jan | journal-article. doi: 10.1023/A:1008266630701.
  • Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy, Experimental Cell Research. 1998 Jan | journal-article. doi: 10.1006/excr.1998.4033.
  • A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion, Annals of Oncology. 1998 Jan | journal-article. doi: 10.1023/A:1008260515869.
  • Drug interactions with the taxanes, Pharmacotherapy. 1997 Jan | journal-article. .
  • Pharmacology of cancer chemotherapy in the older person, Clinics in Geriatric Medicine. 1997 Jan | journal-article. .
  • A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia, Clinical Cancer Research. 1996 Jan | journal-article. .
  • Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia, Journal of Clinical Oncology. 1996 Jan | journal-article. doi: 10.1200/JCO.1996.14.5.1504.
  • Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase, Journal of Clinical Oncology. 1996 Jan | journal-article. doi: 10.1200/JCO.1996.14.12.3085.
  • Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence, Journal of Clinical Oncology. 1996 Jan | journal-article. doi: 10.1200/JCO.1996.14.12.3074.
  • Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy, Cytometry. 1995 Jan | journal-article. doi: 10.1002/cyto.990190208.
  • Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors, Cancer Chemotherapy and Pharmacology. 1995 Jan | journal-article. doi: 10.1007/BF00688317.
  • Should anticancer drug doses be adjusted in the obese patient?, Journal of the National Cancer Institute. 1995 Jan | journal-article. doi: 10.1093/jnci/87.5.333.
  • Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity, Journal of Clinical Oncology. 1994 Jan | journal-article. doi: 10.1200/JCO.1994.12.9.1946.